AI-enabled cardiovascular company Cardio Diagnostics Holdings announced it is partnering with care-navigation platform Navierre to make assessing risk and diagnosing heart diseases more accessible.

CorVista’s AI-based pulmonary capillary wedge pressure add-on test represents the third FDA clearance for its cardiopulmonary ...

CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, today announced the publication of its ...

Cardiovascular diseases remain the leading cause of death worldwide, accounting for nearly 20 million deaths each year. Rapid diagnosis and risk assessment of cardiac injury are therefore essential ...

In a significant advancement for point-of-care medical diagnostics, a team of researchers from UCLA has introduced a deep learning-enhanced, paper-based vertical flow assay (VFA) capable of detecting ...

Heart failure affects 6.5 million people in the U.S., with an additional 550,000 newly diagnosed each year. Heart failure hospitalizations are a leading cause of admissions for those 65 and older, ...

A new study finds that cardiovascular diagnostic testing has yet to return to prepandemic levels in some regions of the world, and that excess pandemic-related stress among physicians and testing ...

Cardio Diagnostics Holdings (NASDAQ: CDIO), an AI-powered precision cardiovascular medicine company, announced that Atlas Healthcare Physicians, an independent physician association serving managed ...

It's common for patients to schedule an office visit due to symptoms like shortness of breath from doing regular tasks, feeling heart palpitations, experiencing mild chest pain, or feeling weak or ...